Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Observer Blind Trial to Compare the Immunogenicity and Acceptability of a MF59-adjuvanted Influenza Vaccine Compared to an Inactivated Influenza Vaccine as a Preferred Influenza Vaccine Priming Strategy for Naive Infants 6 to <24 Months of Age

NCT03669627 is registered in ClinicalTrials.gov with Canadian Immunization Research Network as lead sponsor.

NCT NCT03669627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03669627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Observer Blind Trial to Compare the Immunogenicity and Acceptability of a MF59-adjuvanted Influenza Vaccine Compared to an Inactivated Influenza Vaccine as a Preferred Influenza Vaccine Priming Strategy for Naive Infants 6 to <24 Months of Age
Lead sponsor
Canadian Immunization Research Network
Phase
Phase 2
Overall status
Completed
Start date
November 1, 2018
Completion date
July 21, 2021
Enrollment
159 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

influenza